Talphera Reports Third Quarter 2026 Financial Results and Provides Business Update

Briefing document submitted to FDA for a Sprint Meeting requesting a close of the NEPHRO CRRT study enrollment based on number of patients enrolled as of December 31, 2026 Pivotal NEPHRO study currently exceeds 80% power for primary endpoint supporting a potential early close of...

Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.